However, since the relationship between the clinical response to PD-1 antibodies and the immune status is complicated, monitoring PD-1 expression on tumor infiltrated lymphocytes as well as PD-L1 on tumor cells is clinically impractical and insufficient for most patients. The gene discussed is PDCD1; the disease is neoplasm.